Gainers
- CNS Pharma (NASDAQ:CNSP) shares rose 143.7% to $0.38 during Wednesday's pre-market session. The company's market cap stands at $12.2 million.
- DBV Technologies (NASDAQ:DBVT) stock moved upwards by 62.87% to $1.14. The company's market cap stands at $109.6 million.
- Cyclacel Pharmaceuticals (NASDAQ:CYCC) stock moved upwards by 46.15% to $2.09. The market value of their outstanding shares is at $4.1 million.
- Mustang Bio (NASDAQ:MBIO) shares rose 34.59% to $0.38. The company's market cap stands at $14.1 million.
- LakeShore Biopharma (NASDAQ:LSB) stock rose 25.49% to $3.2. The market value of their outstanding shares is at $61.0 million.
- BioVie (NASDAQ:BIVI) stock increased by 19.34% to $4.01. The market value of their outstanding shares is at $32.0 million.
Losers
- Alto Neuroscience (NYSE:ANRO) shares decreased by 62.3% to $5.48 during Wednesday's pre-market session. The market value of their outstanding shares is at $147.7 million.
- Ensysce Biosciences (NASDAQ:ENSC) shares decreased by 18.58% to $0.44. The company's market cap stands at $6.0 million.
- Genprex (NASDAQ:GNPX) stock decreased by 14.49% to $3.07. The company's market cap stands at $7.9 million.
- TELA Bio (NASDAQ:TELA) shares fell 14.46% to $2.13. The company's market cap stands at $52.6 million.
- Aptevo Therapeutics (NASDAQ:APVO) stock declined by 12.7% to $0.31. The company's market cap stands at $4.1 million.
- Creative Medical Tech (NASDAQ:CELZ) stock declined by 11.51% to $4.0. The market value of their outstanding shares is at $5.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
APVOAptevo Therapeutics Inc
$1.12-0.88%
BIVIBioVie Inc
$1.43-1.57%
CELZCreative Medical Technology Holdings Inc
$2.233.72%
CNSPCNS Pharmaceuticals Inc
$8.407.83%
DBVTDBV Technologies SA
$19.315.12%
ENSCEnsysce Biosciences Inc
$1.41-1.05%
GNPXGenprex Inc
$2.73-3.87%
MBIOMustang Bio Inc
$1.19-0.42%
TELATELA Bio Inc
$1.160.87%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
